ReviewThe Journal of clinical and aesthetic dermatology2026
The Concurrence of Atopic Dermatitis and Alopecia Areata: How Common Is It? Why Does It Happen? How Is This Managed Optimally in Clinical Practice?
Review in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) and alopecia areata (AA) are chronic immune-mediated disorders that frequently coexist in the same patient, an observation noted in both pediatric and adult populations. The clinical implications of a patient experiencing both disease states simultaneously underscores the need for a deeper understanding of pathophysiology of both disease states, how to optimally utilize specific therapeutic options to achieve synergistic outcomes, suggest simplified rational approaches to treatment selection, how to integrate care with other specialists when needed, and hopefully reach the ultimate goal of clinicians incorporating more personalized treatment selection through immunophenotype-guided therapy. This article , based primarily on emerging case reports and off-label data, reviews all the above implications when encountering a patient with both AD and AA. Continued research and real-world clinical evidence are needed in this important area that affects many individuals that clinicians encounter in their practice, including within the pediatric population.
Indexed as
Identifiers
42459245PMC13372308What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.